The content on this site is intended for healthcare professionals only
Dr Natalia Gandur speaks to ecancer about the key bladder cancer and urothelial carcinoma updates presented at ASCO 2026.
She explains that the central theme this year was the integration of systemic therapy, surgery, bladder preservation, toxicity management and patient-centred care across the urothelial cancer pathway.
Dr Gandur discusses the long-term follow-up of enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma, the expansion of this combination into perioperative muscle-invasive bladder cancer, emerging bladder-preservation strategies, and novel immunotherapy approaches.
She also highlights the growing importance of health-related quality of life, biomarkers, toxicity monitoring, multidisciplinary coordination and equitable access as treatment options become increasingly complex.
ASCO 2026: Updates in renal cancer
miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours
Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care
Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer
Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC
AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA
Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC
Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer
TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy
